Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sandro De Filippis"'
Autor:
Pierluigi Pompili, Michele Rosselli, Silvio Rea, Sandro De Filippis, M. Piccinini, Francesco Recchia, Gaetano Saggio
Publikováno v:
American Journal of Clinical Oncology. 24:392-396
5-Fluorouracil (5-FU) given by continuous infusion (c.i.) allows higher dose delivery, causes less myelosuppression, and may interfere with repair of DNA damage caused by epirubicin and cyclophosphamide. With this rationale, we conducted a phase II s
Autor:
Giovanni Corrao, Sandro De Filippis, Francesco Recchia, Giovanna Amiconi, Patrizia Accorsi, Marisa Grimaldi, Antonio Iacone, T. Bonfini, Silvio Rea, Michele Rosselli
Publikováno v:
Journal of Interferon & Cytokine Research. 20:171-178
A trial was conducted to investigate whether the sequential administration of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) could accelerate reconstitut
Autor:
P Torchio, Silvio Rea, Sandro De Filippis, Francesco Recchia, Dennis Quaglino, Alberto Gulino, Luigi Frati
Publikováno v:
American Journal of Clinical Oncology. 20:209-214
This phase I randomized study was designed in order to verify if the sequential administration of filgrastim, a granulocyte colony-stimulating factor (G-CSF), and molgramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF), was superior
Autor:
Francesco, Recchia, Silvio, Rea, Antonio, Nuzzo, Angelo, Lalli, Liberato, Di Lullo, Sandro, De Filippis, Gaetano, Saggio, Edoardo, Biondi, Elena, Massa, Giovanni, Mantovani
Publikováno v:
Anticancer research. 24(3b)
To evaluate the efficacy and safety of oxaliplatin (L-OHP) fractionated over two days with bimonthly 5-fluorouracil (5-FU) and leucovorin (LV), as first-line treatment of metastatic colorectal cancer (MCC) patients.Fifty-four patients with inoperable
Autor:
Francesco Recchia, Silvio Rea, Sandro De Filippis, Giovanna Amiconi, Gaspare Carta, Alisia Cesta, Gaetano Saggio
Oxaliplatin (L-OHP) and stealth pegylated liposomal doxorubicin (PLD) have been shown to be active in pre-treated advanced ovarian cancer (PAOC). The aim of this phase I study was to determine the maximum tolerated dose (MTD) of L-OHP, combined with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6066b0be2fad1abd788a89c1d2fa53d6
http://hdl.handle.net/11697/11300
http://hdl.handle.net/11697/11300
Publikováno v:
Anticancer research. 22(2B)
The objective of this phase II study was to determine the activity and toxicity of gemcitabine, ifosfamide and vinorelbine, in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Chemotherapy-naïve patients with unresectable,
Autor:
Francesco Recchia, Michele Rosselli, Silvio Rea, M. Piccinini, Sandro De Filippis, Gaetano Saggio
Publikováno v:
Europe PubMed Central
Scopus-Elsevier
Scopus-Elsevier
Aims and Background 5-fluorouracil given by continuous infusion allows higher dose delivery, causes less myelosuppression and may interfere with repair of DNA damage caused by carboplatin. With this rationale, we conducted a phase II study to test th
Autor:
Francesco Recchia, Gaetano Saggio, Silvio Rea, Gigliola Sica, Sandro De Filippis, Michele Rosselli
Publikováno v:
Anti-cancer drugs. 13(4)
The aim of the present trial was to Investigate the protective effects on ovarian function, and the efficacy and tolerability of goserelin added to adjuvant chemotherapy for early breast cancer. Following surgical treatment, 64 premenopausal patients
Interleukin-2 and 13-cis retinoic acid in the treatment ofMinimal residual disease. A phase II study
Autor:
Silvio Rea, Francesco Recchia, Sandro De Filippis, Michele Rosselli, Gaetano Saggio, Luca Fumagalli
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
Interleukin-2 (IL-2) which has no cross-resistance with chemotherapy, has given responses in tumors resistant to chemotherapy, and shown to be more effective when tumor burden is low. 13-cis retinoic acid (RA) has immunomodulatory properties, potenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5237a0a0868bc8e6c139ae9a158e5d49
http://hdl.handle.net/11697/17350
http://hdl.handle.net/11697/17350
Autor:
Silvio Rea, Sandro De Filippis, Elisabetta Capomolla, Michele Rosselli, Francesco Recchia, Francesca Fabbri, Angelo Lalli, Marco Lombardo, Gaetano Saggio
Publikováno v:
Cancer. 92(4)
BACKGROUND. Ifosfamide (IFO) and cisplatin (CDDP) are active drugs in the treatment of patients with squamous cell carcinoma (SCC) of the head and neck. 13-Cis retinoic acid (RA), along with its antiproliferative and differentiating activity on SCC c